|Mr. Bruce C. Cozadd||Co-Founder, Exec. Chairman & Chief Exec. Officer||1.84M||N/A||53|
|Mr. Matthew P. Young||Exec. VP & CFO||817.79k||N/A||48|
|Mr. Russell J. Cox||Exec. VP & COO||889.98k||N/A||54|
|Ms. Suzanne Sawochka Hooper||Exec. VP & Gen. Counsel||826.78k||N/A||51|
|Dr. Karen Smith M.D., PH.D., M.B.A., L.L.M||Chief Medical Officer and Exec. VP of R&D||745.85k||N/A||49|
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinsons disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals Public Limited Company’s ISS Governance QualityScore as of November 1, 2017 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 10; Compensation: 9.